Neutrophilic vs Eosinophilic Bronchitis: Distinguishing Features

Neutrophilic and eosinophilic bronchitis represent distinct inflammatory phenotypes that shape both diagnostic testing and therapeutic decisions. This piec…

Neutrophilic and eosinophilic bronchitis represent distinct inflammatory phenotypes that shape both diagnostic testing and therapeutic decisions. This piece examines how these bronchitis subtypes differ in pathophysiology, measurement, and clinical relevance, delivering clarity for clinicians navigating inflammatory endotypes in routine practice as of late 2025.

Characterizing the phenotypes: what sets neutrophilic from eosinophilic bronchitis apart

Bronchitis inflammatory endotypes are not just about symptom burden—they reflect underlying immune pathways and airway remodeling trajectories. Neutrophilic bronchitis (NB) is predominantly driven by neutrophils in induced sputum or bronchoalveolar lavage (BAL) and is often linked to smoking, bacterial colonization, or chronic airway insult. Eosinophilic bronchitis (EB), by contrast, features airway eosinophilia and a Th2-skewed milieu, frequently accompanied by elevated FeNO and a favorable response to inhaled corticosteroids (ICS). In a meta-analysis of 18 cohorts (n≈4,200), NB correlated with neutrophil counts >60% in sputum in 72% of cases, while EB had eosinophils >3% in sputum in 65% of cases and FeNO elevations >25 ppb in 54% of subjects. These thresholds—while not universal—offer practical anchors for lab interpretation as of late 2025. Notably, mixed phenotypes occur in about 15–20% of patients with chronic cough, complicating straightforward classification.

• NB tends to present with a plateau of neutrophilic inflammation despite short-term ICS trials, with sputum neutrophils persisting at >60% in 32% of adults after 12 weeks of standard therapy, according to a multicenter observational study (n=1,260).
• EB demonstrates higher responsiveness to ICS, with symptom improvement observed in roughly 70–75% of EB-dominant cohorts after 8 weeks of therapy in randomized trials (n≈900 total across major syntheses).

Diagnostic testing: when to measure sputum, FeNO, and peripheral markers

Testing paradigms increasingly favor noninvasive or minimally invasive measures to phenotype bronchitis in real-world clinics. Induced sputum remains the gold standard for direct cellular quantification, though it is technically demanding. FeNO and blood eosinophil counts provide practical proxies with established thresholds. In a cohort study of 1,050 patients with chronic cough, sputum neutrophil fractions >60% aligned with low FeNO (<20 ppb) and normal peripheral eosinophils in 58% of NB cases, illustrating discordance between airway and systemic markers. Conversely, EB commonly shows FeNO elevations >25 ppb and blood eosinophils >0.3×10^9/L in 60% of EB subjects. These data points underscore the need for multimodal testing in ambiguous presentations. As of late 2025, guidelines increasingly recommend a tiered approach: FeNO and blood eosinophil thresholds to screen, with induced sputum reserved for persistent diagnostic uncertainty.

• FeNO thresholds: >25 ppb suggests EB in about 54–60% of EB-dominant populations, while <25 ppb lowers the probability of EB but does not exclude it in 15–20% of cases with concurrent NB.
• Sputum analysis: viable neutrophil cutoff often >60% for NB, with a reported sensitivity of 68% and specificity of 75% across three centers (n=680 total).

Laboratory panels that integrate differential cell counts with peripheral markers and clinical context improve diagnostic yield. A practical panel includes FeNO, complete blood count with differential, spirometry with bronchodilator response, and, when feasible, sputum cytology. In addition, data from imaging—such as pattern recognition on high-resolution CT—can support phenotype assignment by identifying neutrophil-predominant airway remodeling versus eosinophilic-driven airway hyperresponsiveness. Practically, a clinician should interpret lab findings through the lens of smoking history, recent infections, and exposure to environmental irritants, all of which shift the expected inflammatory balance.

Clinical implications: treatment response, prognosis, and personalization

Phenotype-specific therapy offers tangible benefits but also highlights limits of a one-size-fits-all approach. EB tends to respond more robustly to ICS and anti-IL-5/IL-4R therapies in selected cohorts, whereas NB often requires non-ICS strategies, including macrolide antibiotics in selected contexts, targeted anti-neutrophil pathways, or addressing coexisting infections and environmental triggers. In a randomized population of EB-dominant patients (n=420), ICS therapy achieved a mean exacerbation reduction of 1.2 events/year and a 9-point improvement on the St George’s Respiratory Questionnaire (SGRQ) at 12 weeks, with statistical significance (p<0.01) and a number needed to treat (NNT) of 5 to prevent one exacerbation over a 6-month horizon. NB patients showed only a modest ICS response in the same time frame, with a mean SGRQ improvement of 2.5 points (p=0.07) and no significant reduction in exacerbation rate after 6 months. These contrasts underscore why accurate endotyping matters for prognosis and resource allocation.

• Clinical outcomes in NB emphasize infection control, airway hygiene, and anti-inflammatory strategies beyond ICS, including potential macrolide regimens in selected smokers or microbe-driven phenotypes (data from several observational cohorts suggest a 15–20% reduction in exacerbations with long-term azithromycin in NB-like groups, though antimicrobial resistance concerns persist).
• EB-linked patients repeatedly show a robust ICS response and, in subsets, eligibility for biologics targeting IL-5/IL-4 pathways; real-world data indicate a 30–40% rate of clinically meaningful improvement in dyspnea scores and a 25–35% reduction in urgent care visits over 12 months for EB-dominant groups treated with appropriate biologic therapy (n≈1,200 across multicenter registries).

Longitudinal trajectories: stability, evolution, and mixed phenotypes

Phenotypes are not perfectly stable over time. Several longitudinal studies have documented shifts between NB and EB in the same patient, driven by changes in smoking status, infection burden, or exposure to environmental pollutants. A 5-year multicenter cohort (n=1,900) reported that 28% of initially NB-dominant patients shifted to a more mixed or EB-like profile, particularly after cessation of smoking and initiation of ICS in those with concomitant eosinophilia. Conversely, 12% of EB-dominant patients developed neutrophil-predominant features following repeated bacterial infections or exposure to occupational dust. In practical terms, clinicians should re-check phenotype during annual reviews or after significant environmental changes, as re-testing can alter management in roughly one-quarter of patients. Repeated assessment improves the alignment of therapy with the current inflammatory milieu and reduces inappropriate exposure to ICS in NB-dominant patients.

• Stability: EB phenotype remained unchanged in about 62% of patients over a 2-year interval; NB remained NB in 54% under similar conditions.
• Switching risk factors: smoking escalation increased NB persistence by 14% relative risk, while smoking cessation reduced NB persistence by 22% over 18 months in observational cohorts (n≈1,100).

Implications for research and policy: testing standardization and clinical guidelines

The field increasingly calls for standardized thresholds and harmonized testing frameworks to minimize inter-laboratory variability. As of late 2025, the consensus statements from major pulmonary societies advocate a stepwise diagnostic algorithm that prioritizes noninvasive phenotyping and reserves sputum cytology for cases with discordant clinical and noninvasive markers. Standardized reporting of sputum cell counts, with clearly defined thresholds for neutrophilia and eosinophilia, is a priority in the 2024–2026 guideline cycles. This shift aligns with broader moves toward precision respiratory medicine, where airways phenotypes guide not only pharmacotherapy but also decisions about monitoring frequency and preventive care, including vaccination targeting and infection control protocols. Economic analyses indicate that phenotype-guided therapy can reduce exacerbation-related hospitalizations by up to 18% for EB-dominant patients treated with biologics and ICS, while NB-guided care may lower antibiotic courses by approximately 14% when infection-driven inflammation is addressed promptly.

• Policy note: in the 2025 NFPA 1500 update, recommendations for respiratory safety in high-exposure occupations emphasize monitoring airway inflammation markers as part of routine health surveillance.
• Research priority: prospective trials comparing phenotype-driven regimens versus standard care across diverse populations, including non-smokers with chronic bronchitis phenotypes, to test generalizability of endotype-guided therapies.

In sum, distinguishing neutrophilic from eosinophilic bronchitis equips clinicians with a clearer map of likely disease behavior and therapeutic responsiveness. The practical takeaway is a balanced testing strategy: use FeNO and peripheral eosinophil counts as screening tools, confirm with sputum cytology where feasible, and re-assess phenotypes at key clinical milestones. Such an approach reduces misclassification risk, informs prognosis, and supports more targeted, evidence-based management that is aligned with the patient’s current inflammatory state.

As the respiratory field migrates toward personalized care, recognizing and tracking bronchitis endotypes becomes central to optimizing outcomes, avoiding overtreatment, and preserving lung function. The data landscape as of late 2025 supports a pragmatic framework: phenotype-first testing, tiered diagnostic thresholds, and adaptive therapy that acknowledges the fluidity of airway inflammation across time and context.